2 min read
KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO
Durham, North Carolina (April 17, 2023) -- KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies,...
Durham, North Carolina (April 17, 2023) -- KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies,...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully.
Geneva, March 21,...
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as...
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Copyright© 2023 Selexis SA. All Rights Reserved.